Catalent Pharma Solutions announced it is investing about $14 million to expand biologics packaging capacity at its Bloomington, Indiana manufacturing facility.
The Somerset-based provider of delivery technologies and development solutions said construction on a new 15,000-square-foot facility is expected to be completed by February 2019. The site will include five new packaging suites, a new quality control laboratory, a syringe assembly machine, an auto-injector assembly machine and two semi-automatic visual inspection machines.
Catalent said the expansion will create 36 new jobs at the site. Catalent’s current 875,000-square-foot facility in Bloomington employs 900.
“This significant investment is due in a large part to Catalent’s extensive expertise in helping customers successfully navigate all stages of development and gain commercial approval for their drug products,” Cory Lewis, vice president and general manager of the Catalent Biologics Drug Product business, said. “The packaging expansion will further enhance our comprehensive end-to-end offering for clinical and commercial customers, complementing the services that Catalent Biologics provides, including cell line development, biologics analytical, biomanufacturing, antibody-drug conjugate development, drug product fill/finish, and clinical supply services.”
